For research use only. Not for therapeutic Use.
GSK-121 Trifluoroacetates a selective PAD4 inhibitor[1].
| Catalog Number | R065573 |
| CAS Number | 1652591-80-4 |
| Synonyms | (3-aminopiperidin-1-yl)-[1-methyl-2-(1-methylindol-2-yl)benzimidazol-5-yl]methanone;2,2,2-trifluoroacetic acid |
| Molecular Formula | C25H26F3N5O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H25N5O.C2HF3O2/c1-26-19-8-4-3-6-15(19)13-21(26)22-25-18-12-16(9-10-20(18)27(22)2)23(29)28-11-5-7-17(24)14-28;3-2(4,5)1(6)7/h3-4,6,8-10,12-13,17H,5,7,11,14,24H2,1-2H3;(H,6,7) |
| InChIKey | CUCLWQZRCAQPJM-UHFFFAOYSA-N |
| SMILES | CN1C2=C(C=C(C=C2)C(=O)N3CCCC(C3)N)N=C1C4=CC5=CC=CC=C5N4C.C(=O)(C(F)(F)F)O |
| Reference | [1]. Drewes G, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91. |
